MEK2 Research at the 2025 N=1 Collaborative Annual Meeting

Our team attended the 2025 N=1 Collaborative Annual Meeting in Budapest to advocate for patients with CFC syndrome and MEK2 mutations, and to advance discussions on personalized treatment development for ultra-rare diseases.

The 2025 N=1 Collaborative Annual Meeting in Budapest, Hungary, brought together individuals living with ultra-rare diseases, as well as the clinicians and scientists working to advance personalized therapies. Our team attended the meeting to highlight the needs of patients with CFC syndrome, particularly those with MEK2 gene mutations, and to discuss our ongoing research initiatives.

The N=1 Collaborative is committed to accelerating the development of individualized medicines for ultra-rare conditions through a global network focused on shared knowledge, open data, and cross-disciplinary collaboration.

We are here together with Maria. The fight for the treatment continues.